Med-tech startup Innovodigm has secured ₹5.5 crore in a seed funding round led by the IAN Group (Indian Angel Network), with IAN contributing ₹4.5 crore and the remaining investment coming from PadUp Ventures.
The Bengaluru-based startup plans to deploy the fresh capital for process optimization, infrastructure expansion, and team growth to support third-party preclinical validations and preparation for upcoming clinical trials.
Innovodigm’s Breakthrough in Vaccine Technology
Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm specializes in micro-array patch (MAP) technology for vaccines, offering an innovative alternative to conventional injectable immunizations. The company’s solution addresses key challenges in vaccination logistics, such as cold-chain dependency, medical waste, and needle-stick injuries.
Unlike traditional vaccines that require refrigeration, Innovodigm’s micro-array patches use thermostabilized vaccines that can remain viable for up to 120 days at 40°C. This temperature resilience significantly improves vaccine accessibility in remote and underserved regions, reducing the reliance on complex cold-chain systems.
Recognitions and Strategic Partnerships
Innovodigm’s MAP technology has gained national recognition and was recently selected among the Top 2 Technologies at the Nano Electronics Showcase 2025 organized by the Ministry of Electronics and Information Technology (MeitY). The company has also signed a Material Transfer Agreement (MTA) with a leading Indian vaccine manufacturer to conduct third-party validation of its platform. The clinical trials for the MAP technology are scheduled to commence next year.
Co-founder and CEO Jhimli Manna emphasized the company’s roots in deep-tech innovation. “Spinning out from IIT Kharagpur’s Microelectronics and MEMS Lab has been fundamental to our scientific foundation. Our MAP platform demonstrates India’s potential to lead in affordable, scalable vaccine delivery that can address both national and global public health needs,” she said.
Future Expansion Plans
Innovodigm is looking to adapt its patch technology for a range of vaccines, including measles, hepatitis, flu, and COVID-19 boosters. The company is also focusing on establishing local manufacturing hubs to ensure patches can be produced close to the regions where they are most needed, particularly in low- and middle-income countries (LMICs).